Methotrexate and early rheumatoid arthritis
- Authors: Bestaev D.V1, Konushkaliev A.A1, Mokhamed Hussein E.E.1
-
Affiliations:
- North Ossetian State Medical Academy
- Issue: Vol 29, No 13 (2022)
- Pages: 142-144
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321145
- DOI: https://doi.org/10.18565/pharmateca.2022.13.142-144
- ID: 321145
Cite item
Open Access
Access granted
Abstract
Recently, indisputable evidence that it is really possible to change the long-term outcomes of rheumatoid arthritis (RA) only at the debut stage of the disease has been obtained. Therefore, the early stage of RA, which is a major medical and social problem, attracts the greatest attention of researchers around the world. The Treat to target (T2T) strategy currently remains the most relevant approach for previously untreated patients with early RA. Early therapy with methotrexate in combination with glucocorticosteroids serves as the basis for T2T. It is emphasized that, despite the potential advantages in efficacy and tolerability, new treatments for RA may be less safe and much more expensive.
Full Text
About the authors
D. V Bestaev
North Ossetian State Medical Academy
Email: davidbestaev@rambler.ru
Dr. Med. (Med.), Head of the Department of Internal Medicine № 33 Vladikavkaz, Russia
A. A Konushkaliev
North Ossetian State Medical AcademyVladikavkaz, Russia
E. E. Mokhamed Hussein
North Ossetian State Medical AcademyVladikavkaz, Russia
References
- Бестаев Д.В., Каратеев Д.Е., Насонов Е.Л. Интерстициальное поражение легких у больных ревматоидным артритом в эру применения генно-инженерных биологических препаратов. Клиническая фармакология и терапия. 2013;22(1):55-61
- Каратеев Д.Е., Лучихина Е.Л., Тогизбаев Г.Современные принципы ведения больных ранним артритом. Русский медицинский журнал. 2008;24:1610
- Grigor C., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263-69. doi: 10.1016/S0140-6736(04)16676-2.
- Conigliaro P., et al. Challenges in the treatment of rheumatoid arthritis. Autoimmun Rev. 2019;18(7):706-13. Doi: 10.1016/j. autrev.2019.05.007.
- Genovese M.C., et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020. doi: 10.1016/s2665-9913(20)30032-1.
- Szekanecz Z., et al. Eight pillars of oncorheumatology: crossroads between malignancies and musculoskeletal diseases. Autoimmun Rev. 2020;19(11):102658. doi: 10.1016/j.autrev.2020.102658
- Figus FA, et al. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4):102776. doi: 10.1016/j.autrev.2021.102776.
- Hadwen B., et al. Risk factors for hypertension in rheumatoid arthritis patients-a systematic review. Autoimmun Rev. 2021;20(4):102786. doi: 10.1016/j.autrev.2021.102786.
- Berger M., et al. Arterial stiffness, the hidden face of cardiovascular risk in autoimmune and chronic inflammatory rheumatic diseases. Autoimmun Rev. 2021;20(9):102891. Doi: 10.1016/j. autrev.2021.102891.
- Atzeni F, et al. Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies? Autoimmun Rev. 2019;18(12):102401. Doi: 10.1016/j. autrev.2019.102401.
- Pawar A., et al. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2020.
- van Vollenhoven R. Treat-to-target in rheumatoid arthritis - are we there yet? Nat Rev Rheumatol. 2019;15(3): 180-86. doi: 10.1038/s41584-019-0170-5.
- Ebrahimian S., et al. Can treating rheumatoid arthritis with disease-modifying anti-rheumatic drugs at the window of opportunity with tight control strategy lead to long-term remission and medications free remission in real-world clinical practice? A cohort study. Clin Rheumatol. 2021;40(11):4485-91. doi: 10.1007/s10067-021-05831-3.
- Heuvelmans J., et al. Effectiveness and tolerability of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis. Rheumatology (Oxford). 2021;61(1):331-36. Doi: 10.1093/ rheumatology/keab313.
Supplementary files
